583 个 · 按相关度排序
Processamento escalável de dados para workloads de ML. Execução em streaming em CPU/GPU, suporta Parquet/CSV/JSON/imagens. Integra-se com Ray Train, PyTorch, TensorFlow. Escala de uma única máquina para centenas de nós. Use para inferência em lote, pré-processamento de dados, carregamento de dados multi-modal ou pipelines distribuídos de ETL.
中文简介正在准备中。当前显示原文说明。
Implementa e valida dados estruturados schema.org em JSON-LD — Organization, Article, FAQPage, Product, BreadcrumbList. Use quando o usuário disser "schema", "dados estruturados", "JSON-LD", "rich snippet", "FAQ schema", "schema.org".
中文简介正在准备中。当前显示原文说明。
对照发布变更与项目文档，更新README、架构图和变更日志，使其与实现一致，并梳理说明缺口及尚未完成的文档任务。
Build threat actor profiles from public reports, social media, code repositories, and other intelligence sources. Correlates indicators, maps related infrastructure and attack techniques, and produces structured dossiers with confidence assessments about who may be responsible.
中文简介正在准备中。当前显示英语简介。
Set up a task list, working memory files, and a dashboard for a productivity system. Use existing todos to clarify nicknames, acronyms, and project codenames, then organize that context into reusable people, terminology, and project notes.
中文简介正在准备中。当前显示英语简介。
Set up a task list, workplace memory files, and a dashboard. Use existing todos to clarify nicknames, abbreviations, and project names, then save that context for future conversations with the agent.
中文简介正在准备中。当前显示英语简介。
Retrieve genes, genetic variants, clinical annotations, and dosing guidelines from the PharmGKB API, then turn the results into concise summaries. Save the full response when you need the underlying data.
中文简介正在准备中。当前显示英语简介。
Use when the user asks to "codify how our founder sounds", "build a founder voice dossier", or "set our content pillars"; runs an 80%-extraction interview over the user's OWN posts, emails, and decks (never competitor scraping, never an invented persona) and produces the versioned voice record — a per-platform register map (incl. 小红书/微信公众号), banned phrases, per-context disclosure lines (the ECHO C2 upstream), a few-shot bank built exclusively from own posts, and 3-5 content pillars with Estimated %-allocations — submitted via memory/events/channels.ndjson for channel-registry to store as voice-dossier.md, the record every Craft-phase skill reads first. Not for the brand-level voice canon — use brand-language-codifier; not for audience/persona research — use audience-mapper. 声音档案/品牌语气/创始人语气/内容支柱/披露声明
中文简介正在准备中。当前显示原文说明。
Configures AWS Shield Advanced for enhanced Distributed Denial of Service (DDoS) protection: subscribing accounts and adding resource protections, enabling automatic application layer (layer 7) mitigation through AWS WAF, configuring health-based detection with Route 53 health checks, setting up Shield Response Team (SRT) access and proactive engagement, reviewing DDoS events and requesting cost protection credits, and aggregating resources into protection groups. Applicable when the user wants stronger DDoS protection for internet-facing resources (CloudFront, Application or Network Load Balancers, Elastic IP addresses, Global Accelerator, or Route 53 hosted zones), wants expert help during an attack, or wants to recover attack-driven scaling charges. Routes to the right per-task procedure in references. Not applicable for authoring AWS WAF rules (waf skill), creating Route 53 health checks (route53 skill), or org-wide Shield Advanced rollout with Firewall Manager (firewallmanager skill).
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Use when the user asks what is pending, what to do next, or to list todos (optionally filtered by area). Lists pending todos, loads full context for the selected one, and routes to work now, add to a phase, brainstorm, or create a phase.
中文简介正在准备中。当前显示原文说明。
This skill should be used when managing the file-based todo tracking system in the todos/ directory. It provides workflows for creating todos, managing status and dependencies, conducting triage, and integrating with slash commands and code review processes.
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Dose-response modeling — EC50 estimation, curve fitting, synergy analysis, and benchmark-dose methods.
中文简介正在准备中。当前显示原文说明。
Verifica la paridad de internacionalización — que cada clave de traducción exista en todos los idiomas y que no haya cadenas visibles para la persona usuaria codificadas de forma fija — siguiendo las convenciones de i18n del proyecto. Úsalo cuando la persona pida revisar las traducciones, verificar la paridad entre idiomas, encontrar cadenas faltantes/codificadas o auditar la i18n (p. ej. "revisa la i18n", "¿están todos los idiomas sincronizados?").
中文简介正在准备中。当前显示原文说明。
Audita una vista o componente frente al design system en lo que un script no puede comprobar — estados de interacción, los cuatro estados de datos, primitivas nativas frente a componentes reinventados y jerarquía visual. Úsalo cuando la persona pida revisar el cumplimiento del design system o si un componente sigue las guías (p. ej. "¿esta tarjeta sigue nuestro sistema?", "audita la vista de ajustes").
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
This skill determines whether confirmatory testing can be omitted after a positive aldosterone-to-renin ratio (ARR) in patients with suspected primary aldosteronism. It is applied when a patient exhibits spontaneous hypokalemia, undetectable renin, and a plasma aldosterone concentration ≥20 ng/dL (550 pmol/L).
中文简介正在准备中。当前显示原文说明。
Calculates salmon calcitonin dose based on patient weight for rapid calcium lowering in hypercalcemia of malignancy. Triggered when a clinician considers rapid calcium lowering and asks about weight‑based calcitonin dosing.
中文简介正在准备中。当前显示原文说明。
This skill interprets the oral sodium loading test for primary aldosteronism by evaluating 24‑hour urinary aldosterone excretion after a high‑sodium diet. Use when reviewing results of an "oral sodium loading test" for PA diagnosis; trigger phrases include "urinary aldosterone excretion ≤10 g/24 h" (PA unlikely) or "≥12 g/24 h (Mayo) / ≥14 g/24 h (Cleveland)" (PA highly likely).
中文简介正在准备中。当前显示原文说明。
Suggests using a low-dose (1 µg) corticotropin stimulation test to diagnose primary adrenal insufficiency when the standard 250 µg corticotropin is unavailable due to drug shortage. Consider this approach when clinicians encounter a corticotropin shortage or when the standard dose cannot be obtained.
中文简介正在准备中。当前显示原文说明。
Determines unilateral vs bilateral aldosterone excess based on cortisol-corrected aldosterone ratios from adrenal venous sampling, with ratio >4:1 indicating unilateral excess, ratio 3:1 suggestive of bilateral hypersecretion, and interpretation dependent on cosyntropin stimulation protocol used during sampling. Use when analyzing AVS results to guide surgical vs medical treatment decisions; triggers include 'AVS lateralization ratio', 'cosyntropin-stimulated AVS', 'aldosterone-to-cortisol ratio >4:1', and 'ratio 3:1 suggestive of bilateral disease'.
中文简介正在准备中。当前显示原文说明。
Recommends fludrocortisone 100 µg daily for children with primary adrenal insufficiency and confirmed aldosterone deficiency; for infants under 12 months, adds sodium chloride supplementation. Triggered by PAI with aldosterone deficiency, evidenced by salt craving, hyponatremia, hyperkalemia, or elevated renin with low aldosterone.
中文简介正在准备中。当前显示原文说明。
Interprets the saline infusion test (SIT) to assess the probability of primary aldosteronism when a patient has a positive aldosterone-to-renin ratio (ARR) and requires confirmatory testing. Triggers include evaluating post‑infusion plasma aldosterone concentration (PAC) after a positive ARR, hypertension work‑up, or when deciding whether to proceed to adrenal venous sampling (AVS).
中文简介正在准备中。当前显示原文说明。